Osimertinib improves progression-free survival in patients with EGFR mutated lung cancer

(European Society for Medical Oncology) Osimertinib improves progression-free survival by 54% compared to standard first line therapy in patients with EGFR mutated non-small-cell lung cancer (NSCLC), according to late-breaking results from the FLAURA trial presented today at the ESMO 2017 Congress in Madrid.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news